ANITOCABTAGENE AUTOLEUCEL
UNII WQD5K35YZT

Substance Identification & Data

This profile provides standardized clinical and technical data for Anitocabtagene Autoleucel, uniquely identified by the FDA Unique Ingredient Identifier (UNII) WQD5K35YZT.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number N/A and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code
WQD5K35YZT
CAS Registry Number
N/A
RxNorm Concept ID
N/A

Detailed Substance Profile

Preferred Name
ANITOCABTAGENE AUTOLEUCEL
Official standardized name for this substance within the FDA UNII nomenclature system.
NCI Thesaurus
C199003
National Cancer Institute reference terminology for clinical and research data.
INN ID
12425
Sequential identifier assigned via the WHO International Nonproprietary Name program.
USAN ID
MN-20
Identifier assigned by the United States Adopted Names Council.
Substance Type
Anitocabtagene Autoleucel
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).
ITIS TSN
180092
Taxonomic Serial Number for species identified in the Integrated Taxonomic Information System.
NCBI Taxonomy
9606
Unique numeric identifier used to specify biological species in the NCBI database.

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Anitocabtagene Autoleucel. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Anitocabtagene Autoleucel

Common Names & Synonyms

ANITOCABTAGENE AUTOLEUCEL [USAN]
Anitocabtagene autoleucel [WHO-DD]
Autologous T lymphocytes obtained from peripheral blood mononuclear cells by leukapheresis, transduced with a self-inactivating, non-replicating lentiviral vector encoding a chimeric antigen receptor (CAR) comprising a three-helix bundle D domain polypeptide (DDpp) targeting human B-cell maturation antigen (BCMA). The expressed transgene comprises a chymotrypsinogen B leader sequence, the anti-BCMA binding domain, a CD8α hinge and transmembrane domain, and a 4-1BB (CD137) and CD3ζ signalling domain, under control of the elongation factor 1 alpha (EF1α) promoter. The construct is flanked by 5' and 3' long terminal repeats (LTRs) and also contains a ψ packaging signal, a central polypurine tract (cPPT) sequence and a Woodchuck hepatitis virus posttranscriptional regulatory element (WPRE). The vector is pseudotyped with vesicular stomatitis virus (VSV) G glycoprotein. The leukapheresis material is enriched for CD4+ and CD8+ T lymphocytes by positive immunoselection. The cells are then activated by CD3 and CD28 agonists and transduced with the lentiviral vector. The cells are further culture expanded in growth media containing interleukin 2 (IL-2) and human AB serum. The cell suspension consists of T lymphocytes (>83%), with greater than 10% of the T lymphocytes expressing the CAR-BCMA transgene. The transduced T lymphocytes demonstrate cytotoxicity against BCMA-expressing cells and secrete interferon gamma (IFN-γ) and IL-2
CART-ddBCMA
anitocabtagene autoleucel [INN]

External Clinical & Regulatory Resources

NCATS
Inxight Drugs
NLM
DailyMed Products
NCATS
GSRS Full Record
NIH
NCI Thesaurus